"It's a brand new way to author work instructions," PTC CEO Jim Heppelmann (pictured) said during his keynote at the company's LiveWorx conference Monday. "It's software that enables humans to ...

The U.S. Food and Drug Administration approved PTC Therapeutics' gene therapy to treat a potential fatal enzyme deficiency ...

Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...

PTC Therapeutics ( (PTCT) ) has released its Q3 earnings. Here is a breakdown of the information PTC Therapeutics presented to its investors.

Analysts expect PTC to post earnings of $1.43 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. PTC (NASDAQ ...

Analyst Jeffrey Hung of Morgan Stanley maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), retaining the price target ...

PTC, Inc. is a global software company, which engages in the provision of a portfolio of innovative digital solutions that work together to transform how physical products are engineered ...

Engineering and design software provider PTC (NASDAQ:PTC ... 3D tours or interactive movies. Reviewing a company’s long-term performance can reveal insights into its business quality.

Vanguard Group Inc. raised its holdings in shares of PTC by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 13,740,919 shares of the technology company’s stock worth $2,596,209,000 after ...

PTC Inc. (PTC) reported $626.55 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 14.6%. EPS of $1.54 for the same period compares to $1.20 a year ago.

Investors interested in PTC should track its annual recurring revenue (ARR) in addition to reported revenue. While reported revenue for a SaaS company can include low-margin items like ...